Strategic Acquisition PathoQuest has recently been acquired by Charles River Laboratories, presenting immediate cross-sell opportunities for integrated biosafety and QA testing services across a broader customer base and expanded global reach.

NGS Biosafety Focus The company specializes in Next-Generation Sequencing based biosafety testing with the iDTECT platform, offering validated GMP assays for viral safety and material characterization—a strong angle for selling enhanced NGS driven testing services to biopharma manufacturers, gene therapy, and vaccine developers.

Geographic Footprint Facilities in Paris and Wayne position PathoQuest to serve both European and North American clients, enabling co-selling with a global CRO network and offering regional regulatory-compliant biosafety testing timelines.

Leadership and Growth Recent leadership additions and commercial appointments indicate a growing emphasis on market expansion and client acquisition; leverage this momentum to propose expanded service scopes, strategic partnerships, and enterprise deals.

Invested Capacity Significant facility investment and a robust funding profile suggest capacity to scale support, enabling long-term collaborations for high-demand programs in biotherapies, cell and gene therapies, and vaccines with rapid turnaround requirements.